证券研究报告 策略 还有哪些行业兼具高景气和性价比？ 2025 年 7 月 06 日│中国内地 策略周报 配置：近期金融及必需消费，中期服务消费、软件及科技硬件 港股市场三季度波动加大，反而提供配置窗口。近期可关注更具性价比和安 全边际的行业如食品饮料、家庭个护及金融，中期景气改善催化的服务消费 （旅游、茶饮、餐饮等）、耐用消费（潮玩、黄金珠宝、服饰等）、科技硬 件、软件服务（云、AI 应用、媒体）仍有配置价值。 中国资产重估受景气支撑，流动性宽松放大重估弹性 2025 年，中国上市企业 EPS 连续第三年上升。EPS 是衡量股权投资回报 的核心指标。MSCI 中国指数 EPS 在 2002~2014 年间年复合增长率 15.7%， 但 2015~2022 年间年复合增长率只有-2.94%。2002~2014 年间，MSCI 中 国指数 ROE 均值 15.4%，2015~2022 年间趋势性降至 10%左右。过去数 年上市公司并未实现每股收益增长，就不难解释为什么指数中枢很难抬升； 但一旦出现阶段性 EPS 预期改善，市场就容易快速反弹，如 2017 年和 2020~2021 年。2023 年以来，ROE ...

Group 1 - BofA Securities analyst Allen Lutz reiterated a Buy rating on Cardinal Health, Inc. and raised the price forecast from $165 to $170, anticipating strong performance and favorable industry dynamics [1][2] - Cardinal Health is set to host an investor day on June 12, where it will provide an updated business outlook and a roadmap for sustained double-digit EPS growth [1][2] - The company is expected to revise its Pharmaceutical and Specialty Solutions EBIT growth outlook upward, with long-term Pharmaceutical EBIT growth targets potentially increasing from 4-6% to 5-7% or 5-8% [2][3] Group 2 - Cardinal Health's prior scale disadvantage in specialty areas is diminishing, and recent M&A activity could have a more significant growth impact compared to larger competitors [6] - The company plans to update its growth path for the Global Medical Products and Distribution segment, addressing tariff impacts and evolving demand trends [7] - The Other segment has shown solid growth, with potential for sustained high-single-digit EBIT growth, while maintaining a balanced capital allocation strategy [8]